SNCA and Parkinson disease: This would target such screening efforts directly at physiologically and pathologically relevant structures, for instance by identifying compounds that selectively bind the pathological conformation of α-Synuclein in brain lysates of PD patients but have no interaction with any proteins in healthy individuals.